What is the address of KW PATHOLOGY?

The registered office of KW PATHOLOGY is located at Jan Tieboutstraat 42, 1731 Asse.

Is KW PATHOLOGY still active?

Yes. According to the CBE (29 September 2026) KW PATHOLOGY is active, legal situation “Normale toestand”, started on 10 February 2022.

Is KW PATHOLOGY registered on Peppol?

No, KW PATHOLOGY is currently not registered on the Peppol network.

What is the enterprise number of KW PATHOLOGY?

The enterprise number of KW PATHOLOGY is BE0781803469.

When was KW PATHOLOGY founded?

KW PATHOLOGY was founded on 10 February 2022.

Who are the directors of KW PATHOLOGY?

According to the 2025 annual accounts, the directors of KW PATHOLOGY are: Kaat Wilgenhof.

Is KW PATHOLOGY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 February 2022; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did KW PATHOLOGY make in 2025?

KW PATHOLOGY posted a profit after taxes of € 8,667 in financial year 2025.

What is the revenue of KW PATHOLOGY?

As a small company, KW PATHOLOGY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 17,602.

KW PATHOLOGY (Private Limited) - Asse - BE0781803469

Dossier KW PATHOLOGY, printed on 29 September 2026 from databakkes.be/en/0781803469/kw-pathology. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

KW PATHOLOGY from Asse, company number BE0781803469, closed financial year 2025 with a result of € 8,667 after tax. For that financial year KW PATHOLOGY recorded a gross margin of € 17,602 and equity of € 88,238. Compared with financial year 2024, the result moved from € 42,781 to € 8,667. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 25, 2025.

What it is worth Growing

€ 88,238

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 8,667

▼ 80% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 65,440

▼ 18% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 84,988.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 5,428

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,030

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,520

▼ 53% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 48,190 Gross margin 2023: € 48,190 First fiscal year in the series	€ 58,103 Gross margin 2024: € 58,103 ▲ 21% vs 2023 (€ 48,190) Favourable step	€ 17,602 Gross margin 2025: € 17,602 ▼ 70% vs 2024 (€ 58,103) Unfavourable step	▼ 70%
Profit after taxes	€ 33,541 Profit after taxes 2023: € 33,541 First fiscal year in the series	€ 42,781 Profit after taxes 2024: € 42,781 ▲ 28% vs 2023 (€ 33,541) Favourable step	€ 8,667 Profit after taxes 2025: € 8,667 ▼ 80% vs 2024 (€ 42,781) Unfavourable step	▼ 80%
Equity	€ 36,791 Equity 2023: € 36,791 First fiscal year in the series	€ 79,572 Equity 2024: € 79,572 ▲ 116% vs 2023 (€ 36,791) Favourable step	€ 88,238 Equity 2025: € 88,238 ▲ 11% vs 2024 (€ 79,572) Favourable step	▲ 11%
Total debts	€ 21,662 Total debts 2023: € 21,662 First fiscal year in the series	€ 27,417 Total debts 2024: € 27,417 ▲ 27% vs 2023 (€ 21,662) Unfavourable step	€ 17,358 Total debts 2025: € 17,358 ▼ 37% vs 2024 (€ 27,417) Favourable step	▼ 37%
Cash	€ 55,577 Cash 2023: € 55,577 First fiscal year in the series	€ 79,349 Cash 2024: € 79,349 ▲ 43% vs 2023 (€ 55,577) Favourable step	€ 65,440 Cash 2025: € 65,440 ▼ 18% vs 2024 (€ 79,349) Unfavourable step	▼ 18%
Retained profit	€ 33,541 Retained profit 2023: € 33,541 First fiscal year in the series	€ 76,322 Retained profit 2024: € 76,322 ▲ 128% vs 2023 (€ 33,541) Favourable step	€ 84,988 Retained profit 2025: € 84,988 ▲ 11% vs 2024 (€ 76,322) Favourable step	▲ 11%
Balance sheet total	€ 58,453 Balance sheet total 2023: € 58,453 First fiscal year in the series	€ 106,988 Balance sheet total 2024: € 106,988 ▲ 83% vs 2023 (€ 58,453) Unchanged	€ 105,596 Balance sheet total 2025: € 105,596 ▼ 1% vs 2024 (€ 106,988) Unchanged	▼ 1%

Key figures of KW PATHOLOGY, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to KW PATHOLOGY?

What happened at KW PATHOLOGY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 25, 2025 New annual accounts for financial year 2025: profit of € 8,667 (▼ 80% vs 2024). Source: NBB ↗
Feb 10, 2022 New establishment in Asse. KBO
2022 Kaat Wilgenhof became a director. NBB
Feb 10, 2022 Start of the company according to the CBE. KBO

In short

From € 33,541 profit in 2023 to € 8,667 profit in 2025.

Paid € 37,226 in corporate taxes since 2023.

Best year ever: 2024, with € 42,781 profit.

Original PDFs at the National Bank ↗

A new publication or filing at KW PATHOLOGY? We notify you, reason included.

Follow KW PATHOLOGY

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Kaat Wilgenhof

KW PATHOLOGY

Behind KW PATHOLOGY is Kaat Wilgenhof.

See the full network in the app

Directors

According to the 2025 annual accounts

Kaat Wilgenhof

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Jan Tieboutstraat 42

1731 Asse

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0781.803.469
VAT number: BE 0781.803.469
Registered office: Jan Tieboutstraat 42, 1731 Asse
Names & denominations: KW PATHOLOGY
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 10 February 2022
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗